ADHD业务
Search documents
Aytu BioPharma outlines $10M EXXUA launch investment and targets breakeven at $17.3M quarterly revenue as ADHD franchise holds strong (NASDAQ:AYTU)
Seeking Alpha· 2025-11-14 02:22
Group 1 - The article does not provide any specific content related to a company or industry [1]
